Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GoPlus: The Skill app, which once topped the ClawHub download charts, is actually a trojan program, and some users have already suffered asset losses.

GoPlus: The Skill app, which once topped the ClawHub download charts, is actually a trojan program, and some users have already suffered asset losses.

ForesightNewsForesightNews2026/02/20 10:11
Show original

Foresight News reported, according to GoPlus monitoring, the Skill "What Would Elon Do," which once topped the ClawHub download charts, is actually a trojan program. Attackers used bots to inflate numbers and manipulate rankings to push it to the top, luring a large number of users to install it.


After installation, this malicious Skill steals users' SSH keys, crypto wallet private keys, and browser cookies, and establishes a reverse shell to the attacker's server, resulting in actual asset losses for users. This incident exposes a serious new supply chain attack vector within the Skill ecosystem. GoPlus reminds users to stop running OpenClaw without proper protection.


Additionally, according to chiefofautism, a total of 1,184 malicious Skills have been found in the entire ClawHub marketplace, with a single attacker uploading 677 malicious packages alone.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475

Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.

智通财经•2026/10/21 07:13

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million

Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.

智通财经•2026/10/21 07:06